The American Society of Clinical Oncology’s ASCO 2013 Annual Meeting kicks off in Chicago May 31. Though the meeting attracts cancer researchers and physicians from around the world, it is closely watched by Wall Street for news of clinical trial results that could send stocks soaring or sinking. We spoke to Adam Feuerstein, senior columnist for TheStreet.com, about a new class of cancer therapies likely to get big attention at this year’s meeting, what other news will be coming out of the conference, and whether concerns about payers willingness to continue meeting the high price commanded by new cancer therapies becomes a topic of discussion in Chicago. Read More
Innovation
- Obama Administration Offers $1 Billion for Healthcare Innovation
HHS awards designed to transform delivery and payment systems. Read More
Deals
- Pharma to Support Early-Stage Biotechs
Roche and Bayer team with QB3 while Atlas Ventures rounds up Amgen and Novartis. Read More
Stem Cells
- Scientists Report Human Stem Cell Cloning Success
Caffeine and healthy cytoplasm promote growth following nuclear transfer. Read More
Court Rulings
- Supreme Court Rules Unanimously in Favor of Monsanto
Judges find Indiana farmer violated company’s patent when he reproduced its biotech seed. Read More
Mental Health
- Saving Normal
Podcast: May 20, 2013 Read More
Dealmaking
- AbbVie Options Alvine Celiac Drug for $70 Million
Collaboration could broaden pharma’s autoimmune pipeline. Read More
Business Models
- Elan Buys Stake in Theravance Royalties on Drugs
Deal gives Irish company a 21 percent stake in future payments associated with four respiratory programs. Read More
Medical Devices
- Carmat to Implant its Artificial Heart in Human Patients
First use of bioprosthetic will take place in four countries. Read More
Obesity
- Lack of Intestinal Bacteria Linked to Obesity
Mice fed a mucus-loving microbe lost weight. Read More
Business Strategy
- Astellas to Consolidate R&D
Japanese pharma plans to outsource some functions while bringing others closer to its headquarters. Read More
- The Burrill Report (May 28, 2013): What Wall Street's Watching at ASCO
Listen to the latest edition from The Journal of Life Sciences. Browse all podcasts
Learn about the essential role remote monitoring will be play in controlling health care costs for Europe's aging population.
Read now
May 2013
Download a free copy of the May 2013 issue of The Burrill Report. Focus on: Q1 Review
Click here to download
Allen Frances, professor emeritus at Duke University and chairman of the DSM IV task force, discusses his criticism of the American Psychiatric Association's fifth edition of its Diagnostic and Statistical Manual of Mental Disorders, or DSM-5, the damage he fears it will cause, and what he calls “the medicalization of normal.”
Capital Scorecard
Filed IPOs
Completed IPOs
PDUFA Dates
Drug Approvals
Burrill Indices
Biggest Movers
Three life sciences companies completed initial public offerings during the second week of May, as the Dow Jones Industrial Average broke the 15,000 mark and the S&P 500 climbed to new highs.
.jpg)
.gif)
.png){kind=small} |
 |